Soluble AXL as a marker of disease progression and survival in melanoma

Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment

(2019) Kayla V. Myers et al.   Molecular Cancer

Targeting of the AXL receptor tyrosine kinase by small molecule inhibitor leads to AXL cell surface accumulation by impairing the ubiquitin-dependent receptor degradation

(2019) Markus Lauter et al.   Cell Communication and Signaling

A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases

(2019) Vivi Ann Flørenes et al.   Translational Oncology

Toward Minimal Residual Disease-Directed Therapy in Melanoma

(2018) Florian Rambow et al.   CELL

The mitogen-activated protein kinase pathway in melanoma part I – Activation and primary resistance mechanisms to BRAF inhibition

(2017) Teresa Amaral et al.   EUROPEAN JOURNAL OF CANCER

Intratumor and Intertumor Heterogeneity in Melanoma

(2017) Tomasz M. Grzywa et al.   Translational Oncology

Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies

(2017) Marie Schoumacher et al.   Current Oncology Reports

Soluble Axl is an accurate biomarker of cirrhosis and hepatocellular carcinoma development: results from a large scale multicenter analysis

(2017) Mirko Dengler et al.   Oncotarget

Accurate Determination of Soluble Axl by Enzyme-Linked Immunosorbent Assay

(2016) Mirko Dengler et al.   ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

(2016) Willy Hugo et al.   CELL

Impact of Expression of Vimentin and Axl in Breast Cancer

(2016) Kimihiro Tanaka et al.   Clinical Breast Cancer

Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy

(2016) M. Scaltriti et al.   CLINICAL CANCER RESEARCH

Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies

(2016) Mihalis S. Kariolis et al.   JOURNAL OF CLINICAL INVESTIGATION

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

(2016) Jesse M. Zaretsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance

(2016) M. A. Miller et al.   Cancer Discovery

Axl-EGFR receptor tyrosine kinase hetero-interaction provides EGFR with access to pro-invasive signalling in cancer cells

(2016) M Vouri et al.   Oncogenesis

The Receptor Tyrosine Kinase AXL in Cancer Progression

(2016) Erinn Rankin et al.   Cancers

Multicenter analysis of soluble Axl reveals diagnostic value for very early stage hepatocellular carcinoma

(2015) Patrick Reichl et al.   INTERNATIONAL JOURNAL OF CANCER

Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial

(2015) Michele Maio et al.   JOURNAL OF CLINICAL ONCOLOGY

An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis

(2014) Mihalis S Kariolis et al.   Nature Chemical Biology

Diversification of TAM receptor tyrosine kinase function

(2014) Anna Zagórska et al.   NATURE IMMUNOLOGY

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

(2014) Georgina V. Long et al.   NEW ENGLAND JOURNAL OF MEDICINE

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma

(2014) Judith Müller et al.   Nature Communications

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

(2012) Zhenfeng Zhang et al.   NATURE GENETICS

Axl-dependent signalling: a clinical update

(2011) Vyacheslav A. Korshunov   CLINICAL SCIENCE

Human Cutaneous Melanomas Lacking MITF and Melanocyte Differentiation Antigens Express a Functional Axl Receptor Kinase

(2011) Marialuisa Sensi et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

R428, a Selective Small Molecule Inhibitor of Axl Kinase, Blocks Tumor Spread and Prolongs Survival in Models of Metastatic Breast Cancer

(2010) S. J. Holland et al.   CANCER RESEARCH

Gas6 is complexed to the soluble tyrosine kinase receptor Axl in human blood

(2010) C. EKMAN et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Differential Expression of Axl and Gas6 in Renal Cell Carcinoma Reflecting Tumor Advancement and Survival

(2009) A. Gustafsson et al.   CLINICAL CANCER RESEARCH

Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival

(2009) C. Gjerdrum et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia

(2008) Chih-Chen Hong et al.   CANCER LETTERS

Axl and Growth Arrest Specific Gene 6 Are Frequently Overexpressed in Human Gliomas and Predict Poor Prognosis in Patients with Glioblastoma Multiforme

(2008) M. Hutterer et al.   CLINICAL CANCER RESEARCH